Raised Expectations About Corona Vaccine Part 1 of Covaxin Phase 1 Completed with Exciting Results'

Serum Institute of India Chairman Adar Poonawalla said that his company will manufacture 100 crore doses of the vaccine in the next one year and provide 50% in half to other poor countries in India.

Phase 1 of the Made in India Covaxin Coronavirus Vaccine Trial (Covaxin) has been completed. More than 50 people were vaccinated across India. The results were encouraging. Six people were vaccinated on Saturday under Part 2 of Phase-1.

Raised Expectations About Corona Vaccine Part 1 of Covaxin Phase 1 Completed with Exciting Results'

With the increase in Coronavirus cases worldwide, including second waves of viruses spread in many countries, it has become clear that only a vaccine against the virus can help the world get rid of this crisis.

On Friday, a 30-year-old man was given indigenous Covid-19 vaccine Covaxin at the All India Institute of Medical Sciences, Delhi. The man was seen for an initial two hours to check for any adverse reactions to the vaccine on his body. All volunteers and their health will be under hospital investigation for more than a year to check for any long term changes / reactions in their body. The vaccine, which has been developed by Hyderabad-based Bharat Biotech in collaboration with ICMR and the National Institute of Virology (NIV), is undergoing clinical trial phase 1 in three medical institutes across the country, with 100 of AIIMS Delhi alone. Is expected to inject more than. Healthy Volunteer with Vaccine.

The other two institutes that started human trials of the vaccine a few days ago are AIIMS Patna and Post Graduate Institute of Medical Sciences (PGIMS) Rohtak. Subsequently, human trials will be initiated in nine other medical institutes of the country which have been selected by the Indian Council of Medical Research (ICMR).

Raised Expectations About Corona Vaccine Part 1 of Covaxin Phase 1 Completed with Exciting Results'

It is worth noting that only individuals who are fit and do not suffer from any form of comorbidity are allowed to become volunteers participating in human trials of the vaccine. After the completion of the first round of clinical trials, the vaccine will be tested on more than 750 people between the ages of 12 and 65 years. More than 3500 individuals have generated interest to volunteer for the vaccine trial at Delhi AIIMS for the Coxaxin Vaccine Candidate.

https://coronavirus237.blogspot.com/2020/07/coronavirus-vaccine-indias-covid-19.html

ZyCov-D update

Another indigenous vaccine that has taken a huge lead in the fight against Covid-19 is the vaccine candidate ZyCoV-D, developed by the Indian pharma Zydus Cadila. Along with covaxin, the vaccine developed by Zydus was also given regulatory approval to begin human trials of the vaccine. The company has so far limited its trial to its Ahmedabad center and is expected to finish all phases of human trials in about seven months time.

A vaccine developed by Oxford University that has already shown its powerful efficacy in making antibodies against the virus in Phase 1 and Phase 2 trials, will also undergo clinical phase trials in India in various parts of the world. The vaccine, previously named Covishield and estimated to cost less than Rs 1000 for a pill, will be administered to more than 5,000 volunteers in the country, Pune-based Serum Institute of India which collaborates with its international manufacturer AstraZena Has been doing.

Oxford vaccine update

On Saturday, the Serum Institute of India (SII) asked the Drugs Controller General of India (DCGI) permission to conduct 2/3 human clinical trials of the potential vaccine. The Pune-based drug firm submitted its application to DCGI on Friday and sought permission to test 'Covishield'. "According to the application, it will conduct an observer-blind, randomized controlled study to determine the safety and immunity of Covishield '(COVID-19) in healthy Indian adults. The firm stated that approximately 1,600 participants over 18 years of age would be enrolled in the study.

Serum Institute of India chairman Adar Poonawalla said that his company will manufacture 100 crore doses of vaccine in the next one year and provide them with up to 50% in India, providing GAVI to the world's poorest countries. (Global Alliance for Vaccine and Vaccination). GAVI is a public-private partnership established by the Bill and Melinda Gates Foundation, which helps poor countries gain equal access to medicines and vaccines.

Raised Expectations About Corona Vaccine Part 1 of Covaxin Phase 1 Completed with Exciting Results'

Global commentary update

On the global front, more than 140 candidates are involved in the development of the vaccine at multiple stages of human and animal trials. The pioneers include Oxford University Vaccine Candidates, US. Drugmaker Pfizer vaccine candidates are vaccines developed by the Chinese Gamalaya Institute of Epidemiology and Microbiology, along with Cancer Biologics of China. A first-stage clinical trial of the first vaccine developed by the organization was described as successful and the organization is now starting a clinical trial of another vaccine developed in the fight against Coronavirus disease from 24 July.

There are a total of 142 vaccine candidates at the pre-clinical-stage worldwide. Further classifying vaccine candidates who are in various stages of clinical trials, a total of 17 vaccines are in the first stage, 13 on the second and only 5 candidates in the phase 3 trials, respectively. It has also been stated that no vaccine has been approved for widespread use in the world and it will take several months for a permanent solution to the Coronavirus virus epidemic in the world.

Scientists identify 21 new drugs to prevent corona, many scientists including Indian origin included

Scientists engaged in the discovery of the Coronavirus vaccine have found another breakthrough. Scientists have identified 21 such drugs that are helpful in preventing the Coronavirus from replicating, ie increasing its number. These drugs were identified during an investigation in the laboratory. Apart from the Sanford Buranam Prebis Medical Discovery Institute of America, scientists from many countries including Indian origin are involved in this research.

Raised Expectations About Corona Vaccine Part 1 of Covaxin Phase 1 Completed with Exciting Results'

Scientists say that in the future, treatment of Coronavirus can be thought of from either of these or a mixture of them. The study, published in the journal Nature, found that these 21 drugs block infection before replicating. Of the drugs that prevent the virus from replicating, 13 are already in clinical trials.

The study states that the dose of these drugs is mixed with Remadecivir. Remadecivir is already reported to be effective in the treatment of Corona. With the help of this, the condition of Corona patients improved quickly. Currently, these 21 drugs are being tested on small animal models. If this is successful, scientists will seek permission from the US Food and Drug Administration (FDA) for a clinical trial.